A tumour found years after lung cancer surgery is usually assumed to be the original cancer returning. Often it is not. It can be a new cancer that has started separately — and a new early cancer generally carries a considerably better outlook than a recurrence. The two look alike on a scan. Comparing the new sample against the original specimen is what tells them apart. Dr Lawrence Okiror performs robotic navigational bronchoscopy to obtain that sample and carries out the surgery that follows. Second opinions at London Bridge Hospital and The Lister Chelsea within 2–3 working days. Self-referrals welcome.
Last reviewed: August 2026 · Dr Lawrence Okiror FRCS(CTh) FRCSEd(CTh) · GMC 6150382
The question here is not how advanced it is. It is which cancer this is — the original one returning, or a new one that has started on its own. Those two answers lead to different treatment and different outlooks, and they cannot be told apart by looking at the new scan.
They are told apart by comparing the new tissue against the specimen removed the first time, which is kept. That comparison exists in one place, and asking for it is reasonable. Request a second opinion within 2–3 days →
Most people who are told about a new shadow years after lung cancer surgery hear it as the cancer coming back. So, often, does the first doctor who sees the scan. The assumption is understandable: you have had lung cancer, and now there is something in your lung again.
But the lungs are a large organ, and whatever caused the first cancer affected all of it rather than only the part that was removed. A second cancer starting independently is not an unusual event. It is common enough that it has its own name — a metachronous second primary, meaning a separate cancer occurring at a different time.
The two situations require quite different responses. A recurrence means the original disease was not fully eradicated, and the question is whether it is now confined to one place. A new primary means the first cancer was dealt with successfully and this is a fresh problem, staged from the beginning as though it were a first diagnosis. More on lung cancer returning after surgery →
The international staging committee that governs how lung cancer is classified reviewed everything available on this question. Only a small number of features are reliable enough to trust on their own: a clearly different type of cancer, matching genetic breakpoints on detailed sequencing, and a careful comparison of the two tumours under the microscope. Scan appearances and marker results are useful pointers but can mislead when relied on alone.1
Two circumstantial factors also count. A long interval between the two makes a new cancer more likely, and a tumour in a different lobe or the opposite lung makes it more likely still. Neither is decisive on its own, but together with the laboratory comparison they usually produce a clear answer.
Your original specimen is kept. The comparison can be made, and it is the only thing that reliably answers the question.
Where it has not been done, the default assumption tends to be the less favourable one — that this is the old cancer returning. That assumption changes the treatment offered, and it is reasonable to ask whether it has been tested.
This is worth stating plainly because the words used tend to obscure it. Being told you have another lung cancer sounds worse than being told the first one has come back. Clinically it is usually the other way around.
A new primary found on a surveillance scan is typically small, confined, and without any lymph gland involvement — the situation in which lung cancer treatment works best. A recurrence, by contrast, is evidence that the original disease survived the first treatment.
None of this makes a second diagnosis easy to receive. But the interpretation matters, and people are entitled to have it explained rather than left with the bleaker reading.
The surgeon removes the tumour and a margin of surrounding lung. What cannot be removed is the exposure that produced it. The rest of the lung has been through the same history, and remains at higher risk than lung that never had that exposure.
This is not a reason for alarm, and it is not a reason to regard the first treatment as having failed. It is the reason follow-up scans continue for years, and the reason those scans are worth attending when you feel perfectly well. More on smoking and lung health →
Most people finish lung cancer treatment and are given a schedule of scans stretching years ahead. The scans can come to feel like a formality, particularly once several have been clear, and it is easy to let them slip.
They are the reason second cancers are found small. A tumour picked up on a routine scan is frequently a centimetre or two across, causing nothing and noticed by nobody — and that is precisely the tumour that can be removed with a small operation and a good outlook. A second cancer that is instead found because it caused symptoms is usually further on.
Robotic navigational bronchoscopy is the most accurate method currently available for sampling small and deeply placed nodules within the lung. It is not yet widely available — the equipment is expensive, the training is specific, and most UK units do not offer it. A three-dimensional map is built from your CT scan and a fine steerable instrument is guided along the airways to the target. You are asleep, there is no incision, and most people go home the same day.
It matters particularly here because second cancers are usually small when found — often too small for other biopsy methods to reach reliably, and precisely the size at which treatment works best. Dr Okiror performs it himself, both in his NHS practice at Guy’s and St Thomas’ and privately at London Bridge Hospital, and carries out the operation that follows. The same surgeon takes the sample, discusses the comparison in the multidisciplinary meeting, and performs the treatment. More on robotic navigational bronchoscopy →
Most second operations are smaller than the first. That is deliberate rather than a compromise: preserving lung tissue matters more the second time, because there is less of it and because a third event cannot be ruled out. An operation designed to take the cancer and as little else as possible protects both breathing and future options.
It is also worth knowing that a second operation is not, in published series, more dangerous than the first. One series of second resections reported no deaths and a complication rate comparable to first operations, most complications being minor.3 That does not remove individual risk, but it does contradict the assumption that having had one operation makes another prohibitive.
A lung is not one structure but a set of segments, each with its own airway and blood supply. That anatomy is what allows a surgeon to remove the affected segment with a proper margin and leave the rest working — and in a lung that has already lost a lobe, that difference frequently decides whether an operation can be offered at all.
It is technically harder in a previously operated chest, and harder again where the new cancer sits close to the site of the earlier surgery. This is where the magnified view and fine instrument control of the robotic platform earn their place. More on robotic segmentectomy →
This is the situation in which lung-sparing surgery matters most. Where lung function looks marginal on a standard breathing test, that test may be understating things. It gives one overall number and cannot show which parts are doing the work. A regional functional scan maps it properly, and where the area being considered for removal was contributing very little anyway, the answer can be more favourable than the numbers first suggested. More on borderline lung function →
Where the two cancers are found at the same time rather than years apart, the situation is different again and is assessed as two simultaneous primaries. More on two lung cancers at the same time →
This is worth addressing directly, because anyone who has had that conversation will remember it. Being told the margin was not clear is unsettling at the time and tends to colour everything afterwards. When a new shadow appears, it is easy for everyone involved to treat the earlier margin as having already answered the question.
It has not. A positive margin is one piece of information alongside the interval since the first operation, the site of the new tumour, and the laboratory comparison. Where a new cancer appears years later, in a different lobe or the opposite lung, and differs from the original under the microscope, it is a new cancer — whatever the first margin showed.
The logic is straightforward. If treatment beforehand reduces a tumour that would have required a lobe to one that can be taken with a segment, the person keeps more lung. In a first cancer that is a benefit. In a second cancer in someone who has already had a resection, it can be the difference between an operation being possible and not.
This is decided in the multidisciplinary meeting with the cancer specialists, based on the stage of the new cancer and what the biopsy shows. More on planned surgery after chemoimmunotherapy →
The assessment is done afresh rather than taken from the first time. Years have passed, and both your lungs and your general condition have changed. Where a standard breathing test looks borderline, a regional functional scan can show whether there is more usable lung than the single number suggests. More on fitness for lung surgery →
Fitness also moves in both directions. It declines with age and with treatment, but it recovers too — someone judged unfit during a difficult period may be a different person a year or two on. A judgement about operability made at a hard moment does not automatically hold years later, and it is reasonable to ask whether it has been revisited.
| Situation | Suggested action |
|---|---|
| New lesion after previous resection, long interval, different lobe or contralateral | Treat as a probable new primary until the comparison says otherwise; stage from the beginning |
| Assumed recurrence without laboratory comparison against the original specimen | Request the comparison — it changes staging, treatment and prognosis |
| Small or deep new nodule, previous resection | Robotic navigational bronchoscopy can reach targets other methods cannot sample reliably |
| Ipsilateral second cancer where completion pneumonectomy is implied | Assess for lung-sparing alternatives before that operation is accepted |
| Previous positive margin, new lesion years later | Not determinative — interval, site and histological comparison decide |
| Borderline lung function after previous resection | Regional functional imaging before concluding surgery is not possible |
Referrals and self-referrals are seen at London Bridge Hospital and The Lister Chelsea, usually within 2–3 working days. Imaging, previous operation notes and the original histology report can be reviewed in advance. Clinic letters go to GPs electronically within two working days, and within three working hours where urgent.
If a new tumour has been described as the original cancer returning and no comparison has been made against the first specimen, that question is worth asking. Most patients are seen within 2–3 working days.
Book a Consultation →Or call Jo Mitchelson:
020 7952 2882
A new tumour years after lung cancer surgery is often a new cancer rather than the old one returning — and that usually means a better outlook and different treatment. The comparison against your original specimen is what answers it. Second opinions at London Bridge Hospital and The Lister Chelsea within 2–3 working days. Self-referrals welcome.
Jo Mitchelson, PA · 020 7952 2882 · pa@lungsurgeon.co.uk
St Thomas’ Hospital #1 UK · Guy’s Hospital #2 UK · London Bridge Hospital #10 UK · Newsweek World’s Best Hospitals 2026
The other interpretation — recurrence rather than a new cancer, and what follows from it.
Two Lung Cancers at the Same TimeWhen two cancers are found together rather than years apart.
Robotic SegmentectomyLung-sparing resection — why second operations are usually smaller than the first.
Robotic Navigational BronchoscopySampling small surveillance-detected nodules through the airways.
Borderline Lung FunctionRegional mapping when a breathing test suggests a second operation is not possible.
Recovery After Lung SurgeryWhat the weeks after an operation involve, and what is different second time.
Smoking and Lung HealthWhy the exposure that caused the first cancer affected the whole lung.
Lung Cancer Second OpinionIndependent review of imaging, staging and treatment plan within 2–3 working days.